Introduction
The following is an update to our previous post describing first-in-the-world exosome treatment successes. These groundbreaking developments span a wide range of neurological and genetic disorders, including:
• Strengthening of ALS patients
• Sustained benefit in Parkinson’s, Lewy Body Dementia, and essential tremor
• Enhanced autism outcomes by combining exosomes with stem cells
• Encouraging results from a new study on stroke
Safety First
We have now completed 300 exosome treatments in 130 unique patients in Antigua with 100% safety and no adverse events of any kind. This milestone underscores the strong safety profile of exosome-based interventions.
ALS: A Breakthrough
A manuscript has been submitted for medical journal publication that documents improvements in most ALS patients—an unprecedented development. Notably, most patients have actually gotten stronger, a first in ALS treatment. While two patients initially improved and are now declining again, we continue to treat patients every 2–3 months in Antigua. We are also close to developing stronger exosomes for the more resistant cases.
Parkinson’s Disease
Among 19 Parkinson’s patients with 3-month to 1-year follow-up, 15 have improved, suggesting potential disease-modifying activity. One patient, a fitness trainer, has completely eliminated symptoms and stopped all medications for two months with no recurrence. He recently won second place in a senior’s bodybuilding contest.
A video of one such patient is available here: Exosome Treatment for Parkinson’s
Alzheimer’s Syndrome and New Study
Our success rate so far has been only 40%. To improve outcomes, we have launched a new study involving exosomes and a higher dose of stem cells. Results are expected in approximately four months.
Autism
Past stem cell treatments yielded positive results. However, our most recent patients who combined stem cells with exosomes experienced significantly better overall outcomes, including one patient achieving a better result than any seen before using stem cells alone.
Brain Fog and Early Cognitive Decline
We have treated six middle-aged or elderly patients experiencing cognitive issues. All reported significantly improved cognition, such as enhanced focus and short-term memory. These results outperformed stem cell therapy—at about half the cost.
Essential Tremor
All patients with essential tremor treated with exosomes have shown positive results. A video is available to demonstrate this: Video of Patient with Essential Tremor.
Kennedy Disease and Congenital Myasthenic Syndrome
These rare, debilitating genetic disorders lack effective treatments. While we informed patients that our therapies would not correct underlying genetic defects, both opted to proceed without charge. Both experienced remarkable, transformative improvements. Testimonials and videos are being prepared.
Excellent results in Stroke Patients
A long time patient had a stroke 7 months ago leaving him with brain fog, focus and memory issues as well as balance and gait problems. After two treatments with exosomes on consecutive days his cognitive issues completely disappeared with full return of focus, thought and memory. His gait issues also completely disappeared. When I asked him to walk to test his gait after treatment he asked if he could “skip.” He then proceeded to skip flawlessly where he had previously had issues even walking
A second patient had a stroke 3.5 years prior to treatment. After two treatments his motor function was substantially improved and his brain fog almost completely gone.
These patients are only 2 weeks post treatment, so they could regress. But based on Parkinson’s and ALS we think it unlikely. In fact we expect stroke patients to have best prognosis of all neurodegenerative disorders because there is no degenerative process as is present in ALS and Parkinson’s to fight the healing and improvement.
Advocacy with HHS and RFK Jr.
I was recently invited by RFK Jr. to speak at HHS in Washington, D.C. about expanding access to stem cells in a controlled, responsible way—avoiding a “wild west” environment. The talk was well received, and I remain in active discussions to help shape these important policy changes. I was invited back in two weeks for discussions with FDA leadership in this regard.
Conclusion
With continued improvements across multiple difficult-to-treat conditions, our exosome and stem cell therapies offer promising new avenues of care. We remain committed to safety, innovation, and ethical accessibility.
To contact the Prodromos Stem Cell Institute please visit:
https://www.stemcellcouncil.com/the-prodromos-stem-cell-institute
